Comparative safety of newer oral antidiabetic drugs

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Expert Opinion on Drug Safety

• Publication date

  2006-10-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14740338.5.6.827PMID 17044809
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Role of Sulphonylureas in the Management of Type 2 Diabetes Mellitus

  2012cited by this paper
• Oral Antidiabetic Agents

  2012cited by this paper
• Metabolic and Additional Vascular Effects of Thiazolidinediones

  2012cited by this paper
• Traitement médicamenteux du diabète de type 2 (deuxième partie)

  2007cited by this paper
• PPAR gamma and human metabolic disease.

  2006cited by this paper
• Dose–response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study

  2006cited by this paper
• Sulfonylureas and the risk of myocardial infarction.

  2006cited by this paper
• PPARγ and human metabolic disease

  2006cited by this paper
• Glucose lowering and diabetes prevention: are they the same?

  2006cited by this paper
• What has prevented the expansion of insulin sensitisers?

  2006cited by this paper
• Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues.

  2006cited by this paper
• Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

  2006cited by this paper
• The DREAM trial – Authors' reply

  2006cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper
• Effects of Angiotensin Converting Enzyme Inhibition in Patients With Stable Coronary Artery Disease: The Prevention of Events With Angiotensin Converting Enzyme Inhibition (PEACE) Trial: The PEACE Study Investigators

  2005cited by this paper
• Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation.

  2005cited by this paper
• Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.

  2005cited by this paper
• The PROactive study: some answers, many questions.

  2005cited by this paper
• A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.

  2005cited by this paper
• Thiazolidinediones.

  2004cited by this paper
• GUIDE study: double‐blind comparison of once‐daily gliclazide MR and glimepiride in type 2 diabetic patients

  2004cited by this paper
• Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association

  2003cited by this paper
• Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

  2003cited by this paper
• Textbook of type 2 diabetes

  2003cited by this paper
• Acarbose for the prevention of diabetes.

  2003cited by this paper
• Sulfonylureas in the prevention of vascular complications: from UKPDS to the ADVANCE study

  2003cited by this paper
• Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function.

  2003cited by this paper
• Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?

  2003cited by this paper
• Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience.

  2003cited by this paper
• Hypoglycaemic Agents for Type 2 Diabetes mellitus

  2003cited by this paper
• Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

  2002cited by this paper
• Pharmacological modulation of K(ATP) channels.

  2002cited by this paper
• Role of AMP-activated protein kinase in mechanism of metformin action.

  2001cited by this paper
• Optimisation of the Management of Patients with Coronary Heart Disease and Type 2 Diabetes Mellitus

  2001cited by this paper
• Insulinotropic meglitinide analogues.

  2001cited by this paper
• Insulin-lowering drugs in polycystic ovary syndrome.

  2001cited by this paper
• Pharmacological modulation of KATP channels

  2001cited by this paper
• [Thiazolidinediones in type 2 diabetes].

  2000cited by this paper
• 胰岛素增敏剂一Thiazolidinediones研究现状

  2000cited by this paper
• Meglitinide Analogues in the Treatment of Type 2 Diabetes Mellitus

  2000cited by this paper
• Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.

  2000cited by this paper
• Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.

  2000cited by this paper
• Thiazolidinediones: a new class of antidiabetic drugs

  1999cited by this paper
• A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

  1999cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998influential reference
• Comparative Tolerability Profiles of Oral Antidiabetic Agents

  1994cited by this paper
• A Summary of Criticisms of the Findings and Conclusions of the University Group Diabetes Program (UGDP)

  1972cited by this paper

• Cedrin Mitigates Dyslipidemia, Inflammation, and Oxidative Stress in Streptozotocin-induced Diabetes Mellitus in Rats

  2025cites this paper
• Comparative study of cortisol and leptin concentration in obese non-diabetics and obese with uncomplicated diabetes

  2024cites this paper
• Quercetin, a Plant Flavonol Attenuates Diabetic Complications, Renal Tissue Damage, Renal Oxidative Stress and Inflammation in Streptozotocin-Induced Diabetic Rats

  2023cites this paper
• Antidiabetic effect of the scorpion Scorpio maurus palmatus body extract using alloxan-induced diabetic mice model

  2019cites this paper
• Glucose‐lowering drugs

  2017cites this paper
• Implications physiopathologiques de la Nestine lors du remodelage pulmonaire et cardiaque à la suite de l’infarctus du myocarde, du diabète et de l’hypertension pulmonaire

  2016cites this paper
• 1-Deoxynojirimycin: Occurrence, Extraction, Chemistry, Oral Pharmacokinetics, Biological Activities and In Silico Target Fishing

  2016cites this paper
• Thiazolidinediones versus metformin on improving abnormal liver enzymes in patients with type 2 diabetes mellitus: a meta-analysis

  2015cites this paper
• Identification of possible adverse drug reactions in clinical notes: The case of glucose-lowering medicines

  2015cites this paper
• Safety Pharmacology assessment of drugs with biased 5-HT(2B) receptor agonism mediating cardiac valvulopathy.

  2014cites this paper
• PPAR's and Diosgenin a chemico biological insight in NIDDM.

  2013cites this paper
• The choice of oral hypoglycemic agents: the current view of the problem

  2013cites this paper
• Carboxymethylcellulose sodium improves the pharmacodynamics of 1-deoxynojirimycin by changing its absorption characteristics and pharmacokinetics in rats.

  2012cites this paper
• Drug-Induced Hypoglycaemia

  2011cites this paper
• Hypersensitivity to repaglinide.

  2011cites this paper
• Scorpion in Combination with Gypsum: Novel Antidiabetic Activities in Streptozotocin-Induced Diabetic Mice by Up-Regulating Pancreatic PPARγ and PDX-1 Expressions

  2011influential citation
• Type 2 Diabetes: An Expanded View of Pathophysiology and Therapy

  2010cites this paper
• Future perspectives for insulinotropic agents in the treatment of type 2 diabetes–DPP‐4 inhibitors and sulphonylureas

  2010cites this paper
• Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications

  2009cites this paper
• Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone.

  2009cites this paper
• Treating type 2 diabetes: how safe are current therapeutic agents?

  2009cites this paper
• Part B of the proposal Short web-based version Proposal full title : New technologies for targeted metabolomics

  2008cites this paper
• Antidiabetic Treatment in Obese Patients with Type 2 Diabetes - Effects of Medication on Bodyweight

  2006cites this paper
• Vascular Health and Risk Management Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Cardiovascular Disease and Intensive Glucose Control in Type 2 Diabetes Mellitus: Moving Practice toward Evidence-based Strategies

  year unknowncites this paper